Sun Yat-sen University
1,925
402
500
426
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
3.5%
68 terminated/withdrawn out of 1925 trials
86.2%
-0.4% vs industry average
19%
364 trials in Phase 3/4
5%
21 of 426 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (1925)
Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia
Role: lead
Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Role: lead
Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma
Role: lead
Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial
Role: lead
HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
Role: lead
Dry Eye Screening and Referral System
Role: lead
Neoadjuvant Immunochemotherapy for LAOSCC
Role: collaborator
Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
Role: lead
Multi-Theory Model-Based AI Agent Intervention for Smoking Cessation in Early-Stage Cancer Patients
Role: lead
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
Role: lead
Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial
Role: lead
Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma
Role: lead
High Quality Evidence of Chinese Lupus Nephritis (HELP)
Role: lead
Super Chinese Nephrotic Syndrome Registration System (SUCCESS)
Role: lead
Peritoneal Dialysis Registration System (PERSIST)
Role: lead
Wise Practice of Chinese Hemodialysis (WISHES)
Role: lead
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Role: lead
IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
Role: lead
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.
Role: lead
ICF-Based Interdisciplinary Case Management for Individuals With Disabilities
Role: collaborator